| P2093 | author name string | Chung-Feng Huang | |
| | Ming-Lung Yu | |
| P2860 | cites work | Extrahepatic manifestations of chronic hepatitis C virus infection | Q26767084 |
| | A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C | Q27478337 |
| | Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 |
| | Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence | Q29616009 |
| | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 |
| | Sofosbuvir for previously untreated chronic hepatitis C infection | Q29620137 |
| | Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. | Q30361098 |
| | Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study | Q31168033 |
| | Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. | Q31168457 |
| | Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study | Q33435950 |
| | Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database | Q33765497 |
| | Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus | Q34044333 |
| | Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection | Q34067956 |
| | Association of age-dependent liver injury and fibrosis with immune cell populations | Q34118689 |
| | Does hepatitis C virus infection increase risk for stroke? A population-based cohort study | Q34171033 |
| | Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? | Q34537738 |
| | Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study | Q35596325 |
| | Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy | Q42992092 |
| | Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. | Q42996403 |
| | Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. | Q44010419 |
| | Clinical outcomes after transfusion-associated hepatitis C. | Q44746801 |
| | Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy | Q45164435 |
| | Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention | Q45355364 |
| | Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants | Q45406535 |
| | Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon | Q46381851 |
| | Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. | Q47878759 |
| | Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C | Q58622591 |
| | Viral hepatitis C. | Q35617324 |
| | Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients. | Q35773677 |
| | Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens | Q35783876 |
| | Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan | Q36009124 |
| | Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis | Q36220536 |
| | Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection | Q36505470 |
| | World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma | Q37248638 |
| | Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy | Q37328172 |
| | Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort | Q37398996 |
| | Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C | Q37651899 |
| | Chronic hepatitis C infection in the elderly | Q37972329 |
| | Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. | Q38376150 |
| | The prevalence of hepatitis C in England and Wales. | Q38486903 |
| | Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden | Q38753964 |
| | Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. | Q38876972 |
| | Hepatitis C: efficacy and safety in real life. | Q39040719 |
| | Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. | Q39099624 |
| | Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens | Q39104215 |
| | Visualization of stem cell features in human hepatocellular carcinoma reveals in vivo significance of tumor-host interaction and clinical course. | Q39187561 |
| | Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response | Q39449507 |
| | Community-based seroepidemiological survey of HCV infection in Catalonia, Spain | Q39587848 |
| | Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study | Q39599901 |
| | Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. | Q39690146 |
| | Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients | Q39821108 |
| | Epidemiology of HCV infection in the general population: a survey in a southern Italian town. | Q39894850 |
| | Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. | Q39920086 |
| | Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older | Q40171094 |
| | Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients | Q40333753 |
| | Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B. | Q40434252 |
| | Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. | Q40478943 |
| | Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study | Q40484806 |
| | Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment | Q40509070 |
| | The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection | Q40567336 |
| | Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis | Q40689148 |
| | Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study. | Q40903867 |
| | Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection | Q41628819 |
| | Progression to cirrhosis in hepatitis C patients: an age-dependent process | Q42168870 |
| | Efficacy and safety of telaprevir-based antiviral treatment for elderly patients with hepatitis C virus | Q42180573 |
| | Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program. | Q42209774 |
| | Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication | Q42232663 |
| | Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. | Q42247557 |
| | Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. | Q42978706 |
| | Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients | Q42988204 |
| | Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. | Q42990691 |
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1867-1874 | |
| P577 | publication date | 2017-10-31 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments | |
| P478 | volume | 18 | |